This IP is designed to target and treat cancers resistant to conventional therapies, and the technology involves genetically modified herpesviruses that selectively replicate within malignant cells, leading to their destruction. The virus triggers inflammatory responses and recruits immune cells, which converts an immune-unresponsive tumor into an immune-active environment. Notably, the oHSV expresses interleukin-12 (IL-12), a cytokine that enhances the activity of immune cells like T and NK cells, further boosting the anti-tumor immune response. The IP offers several advantages over existing methods. Firstly, it improves IL-12 production and extends the duration of immune activation, ultimately enhancing therapeutic effects against tumors. Secondly, it has shown promise in converting cold tumors into hot tumors, making them more susceptible to immune-mediated destruction. This versatility makes it applicable across various cancer types, including those that have shown resistance to other treatments. Compared to earlier generation IL-12 expressing oHSVs, this innovation demonstrates improved IL-12 production and activity in some models. Its ability to modulate immune cell function within the tumor microenvironment sets it apart from traditional cancer therapies. Further development of this technology involves characterizing the immune mechanisms underlying its response and exploring combination therapies to enhance its efficacy. Ongoing pre-clinical studies aim to investigate its compatibility with engineered cell therapies, such as CAR-T and CAR-NK cells, expanding its potential applications in adoptive cellular therapy. The IP stands to transform cancer treatment by providing a more targeted and effective therapy option, especially for patients who have failed conventional treatments. Pharmaceutical companies focusing on immunotherapy and cellular therapy, as well as those developing oncolytic virus-based treatments, are likely to be interested in licensing this technology for further development and commercialization.